Maemondo et al. reported that treatment with gefitinib achieved a longer median progression-free survival (PFS) of 10.8 months and a higher response rate of 73.7% compared with standard chemotherapy in NSCLC patients with EGFR mutations [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.